* Achieve Life Sciences Inc is expected to show no change in quarterly revenue when it reports results on November 7 for the period ending September 30 2024
*
* LSEG's mean analyst estimate for Achieve Life Sciences Inc is for a loss of 26 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Achieve Life Sciences Inc is 13.00, above its last closing price of $4.85.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jan. 1 0001 -0.23 -0.23 -0.25 Missed -7.9
Mar. 31 0001 -0.25 -0.24 -0.26 Missed -6.6
Jan. 1 0001 -0.31 -0.31 -0.26 Beat 17.3
Jan. 1 0001 -0.37 -0.38 -0.34 Beat 10.2
Jun. -0.41 -0.42 -0.43 Missed -2
30 2023
Mar. 31 2023 -0.68 -0.69 -0.50 Beat 27.1
Dec. 31 2022 -0.77 -0.83 -0.83 Met 0
Sep. 30 2022 -1.14 -1.13 -1.35 Missed -19.8
This summary was machine generated November 6 at 05:03 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。